A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

15401ALLO-501A-202-NCT06500273OpenA RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)ALLO-501A-202NCT06500273IndustrialAdultTreatmentIIGlobalOtherDunleavy, KieronGeorgetown University Medical Center : Stephanie Wagner; Lombardi Comprehensive Cancer Center : Stephanie WagnerCell Therapy; LymphomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); OMI; Oncology PFS8343Stephanie WagnerStephanie Wagner+1 202-687-9782sw1095@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>